• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

    8/12/24 4:05:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email

    - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials

    - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC

    - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024

    - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025

    REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the second quarter of 2024 and provided Ixo-vec program and corporate highlights.

    "The LUNA trial was designed to answer a key question – whether lower doses of Ixo-vec with enhanced prophylactic regimens could demonstrate a product profile consistent with or better than that demonstrated in OPTIC. At ASRS, we presented LUNA interim analysis results that demonstrate we've achieved this objective and, further, that Ixo-vec at 6E10 with local prophylaxis represents a potential best-in-class product profile. Taken together, these results support our selection of the 6E10 dose for Phase 3 pivotal studies," stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "Importantly, our development program builds on the long-term Ixo-vec results from the OPTIC study. In OPTIC, even with suboptimal prophylaxis, 14 of 15, or 93%, of 2E11 patients were free of inflammation at 1 year and 100% were inflammation free at 2 years after Ixo-vec treatment. When present, inflammation was successfully treated with topical corticosteroids. In LUNA, the analysis at the 26-week mark demonstrated an industry-leading proportion of patients free from injections, and there was an improved safety profile compared to OPTIC. In addition, we believe the LUNA pre-specified patient preference survey speaks to the overall best-in-class profile of Ixo-vec, with 93% of patients responding they would use Ixo-vec in their fellow eye. In the fourth quarter of this year, we look forward to presenting landmark 9-month data, as well as to providing updates on the design of our pivotal program."

    Ixo-Vec Program Highlights:

    • LUNA 26-Week Interim Analysis Presented at the 2024 ASRS Annual Meeting:
      • In July 2024, we announced results from the landmark 26-week interim analysis of the ongoing LUNA Phase 2 trial of Ixo-vec in patients with wet age-related macular degeneration (AMD). These data were presented by Dr. Charles Wykoff at the 42nd Annual Meeting of the American Society of Retinal Specialists in Stockholm, Sweden.
        • 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control.
        • Ixo-vec was well-tolerated, and the enhanced local corticosteroid prophylaxis in LUNA resulted in an improved inflammatory profile as compared to OPTIC.
        • Of the patients receiving 6E10 and the difluprednate-alone prophylactic regimen, 100% responded that they would prefer Ixo-vec therapy over the prior treatments received and that they would want to receive Ixo-vec in the fellow eye.
      • 6E10 dose selected for Phase 3 pivotal trials due to its favorable safety and potential best-in-class product profile
    • Ixo-vec Received Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA:
      • In August 2024, we announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation for Ixo-vec for the treatment of wet AMD. The RMAT designation is based on the clinical data from Ixo-vec to date and recognizes the transformative potential of our gene therapy for patients with wet AMD. RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including potential priority review of the biologics license application (BLA) and other opportunities to expedite development and review.

    Corporate Highlights

    • Appointed Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors:

    In June 2024, we announced the appointment of Dr. Rabia Gurses Ozden to the Company's executive leadership team as chief medical officer and of Dr. Szilárd Kiss to the Company's Board of Directors. In connection with her appointment as chief medical officer, Dr. Ozden stepped down from the Company's Board of Directors, with Dr. Kiss filling the resulting vacancy.

    Upcoming Anticipated Milestones

    • 2H 2024: Continued FDA and EMA formal and informal regulatory interactions
    • 4Q 2024: Clinical data from the landmark LUNA 9-month analysis
    • 4Q 2024: Phase 3 pivotal trial design update
    • 1Q 2025: Clinical data from the landmark LUNA 52-week analysis
    • H1 2025: Planned initiation of Phase 3 trial

    Financial Results for the Three Months Ended June 30, 2024

    • Cash, cash equivalents and short-term investments were $173.8 million as of June 30, 2024, compared to $96.5 million as of December 31, 2023. Adverum expects its cash, cash equivalents and short-term investments to fund operations into late 2025.
    • Research and development expenses were $17.1 million for the three months ended June 30, 2024, compared to $20.6 million for the same period in 2023. Research and development expenses decreased due to lower facilities related expenses and lower compensation expenses. Stock-based compensation expense included in research and development expenses was $1.1 million for the second quarter of 2024.
    • General and administrative expenses were $3.8 million for the three months ended June 30, 2024, compared to $12.5 million for the same period in 2023. General and administrative expenses decreased due to a cumulative catch-up adjustment of sublease income, lower facilities related expense, lower depreciation expense, and lower insurance expense driven by lower premiums. Decreases were partially offset by increased compensation expense and professional services expense. Stock-based compensation expense included in general and administrative expenses was $2.9 million for the second quarter of 2024.
    • Net loss was $18.5 million, or $0.89 per basic and diluted share, for the three months ended June 30, 2024, compared to $31.5 million, or $3.13 per basic and diluted share for the same period in 2023.

    About Wet Age-Related Macular Degeneration

    Wet AMD, also known as neovascular AMD or nAMD, is a VEGF-driven advanced form of age-related macular degeneration (AMD) associated with the build-up of fluid in the macula and the retina. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases. Additionally, wet AMD is a bilateral disease, and incidence of nAMD in the second eye is up to 42% in the first two to three years. The current standard of care requires frequent life-long bolus injections of anti-VEGF in the eye. Intravitreal (IVT) gene therapy has the promise to preserve vision and reduce most or all injections for the life of the patient by delivering stable therapeutic levels of anti-VEGF to control fluid associated with the disease.

    About Ixo-vec in Wet AMD

    Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician's office, deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections into the eye, optimize patient compliance and improve vision outcomes for patients with wet AMD. Ixo-vec is currently being evaluated for the treatment of neovascular or wet AMD in the ongoing LUNA Phase 2 clinical trial (NCT05536973) and the OPTIC Phase 1 extension study (NCT04645212). In recognition of the need for new treatment options for wet AMD, FDA has granted Fast Track and RMAT designations for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the European Medicines Agency and the Innovation Passport from the United Kingdom's Medicines and Healthcare products Regulatory Agency for the treatment of wet AMD.

    About Adverum Biotechnologies

    Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

    Forward-looking Statements

    Statements contained in this press release regarding events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the favorable safety profile and potential best-in-class product profile of Ixo-vec, anticipated timing of interim data and trial design update for the Phase 2 LUNA trial and initiation of a Phase 3 trial, and the Company's cash sufficiency and runway. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum's novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties; the results of early clinical trials not always being predictive of future clinical trials and results; the potential for future complications or side effects in connection with use of Ixo-vec; and risks associated with market conditions. Additional risks and uncertainties facing Adverum are set forth under the caption "Risk Factors" and elsewhere in Adverum's Securities and Exchange Commission (SEC) filings and reports, including Adverum's most recent Annual Report on Form 10-K filed with the SEC, as updated by any subsequent reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Corporate, Investor and Media Inquiries

    Adverum Biotechnologies, Inc.

    E: [email protected]

     
    Adverum Biotechnologies, Inc.
    Consolidated Balance Sheets
    (In thousands)
        
     June 30 December 31
     2024 2023
     (Unaudited) (1)
    Cash, cash equivalents, and marketable securities$173,827 $96,526 
    Total assets 253,803  173,010 
    Total current liabilities 22,461  24,914 
    Total stockholders' equity 168,029  83,469 
        

    (1) Derived from Adverum's annual audited consolidated financial statements.

     
    Adverum Biotechnologies, Inc.
    Consolidated Statements of Operations
    (In thousands except per share data)
            
     Three months ended June 30, Six months ended June 30,
      2024  2023  2024  2023
     (Unaudited)
            
    License revenue$—     $—  $-  $3,600 
            
    Operating expenses:       
    Research and development 17,097   20,599   32,507   41,658 
    General and administrative 3,785   12,466   15,214   25,246 
    Total operating expenses 20,882   33,065   47,721   66,904 
    Operating loss (20,882)  (33,065)  (47,721)  (63,304)
    Other income, net 2,406   1,576   4,458   2,776 
    Net loss before income taxes (18,476)  (31,489)  (43,263)  (60,528)
                    
    Income tax provision —   (21)                         —   (38)
    Net loss$(18,476) $(31,510) $(43,263) $(60,566)
    Net loss per share — basic and diluted$(0.89) $(3.13) $(2.31) $(6.02)
    Weighted-average common shares outstanding - basic and diluted 20,852   10,077   18,713   10,054 


    Primary Logo

    Get the next $ADVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Adverum Biotech with a new price target

      Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

      6/25/24 8:10:21 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

      H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

      4/30/24 6:15:49 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotech upgraded by Truist with a new price target

      Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00

      7/7/22 7:11:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:57:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:40:56 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 4:05:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adverum Biotechnologies Inc.

      SCHEDULE 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      5/6/25 9:15:54 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

      DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:02:59 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adverum Biotechnologies Inc.

      DEF 14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:01:46 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADVM
    Financials

    Live finance-specific insights

    See more

    $ADVM
    Leadership Updates

    Live Leadership Updates

    See more

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

      REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

      7/10/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

      - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

      2/1/24 5:30:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

      REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

      12/7/23 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

      - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

      11/4/24 4:39:45 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

      10/16/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

      - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

      8/12/24 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common

      5/2/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

      REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. "We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-class, one-and-done gene therapy. Ixo-vec offers the potential for life-long vision preservation and a favorable safety profile and is overwhelmingly preferred by patients over tod

      4/15/25 7:40:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $3.83 per share, Adverum's closing trading price on the grant date, and will vest over four years,

      4/4/25 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care